"We will be ready to launch the pentavalent vaccine at the end of 2012," PT Bio Farma spokesman Nurlaela said here on Friday.
Pentavalent vaccine is a combination of five different vaccines, namely difteri, pertusis, tetanus, hepatitis B and hermophilusinfluenza of type B (HIB).
Other pentavalent vaccine producing countries include the United States, Belgium and France.
Nurlaela said the company would sell the vaccine abroad after securing a certificate from the World Health Organization (WHO).
She added that with the help of the global body, the company would market the vaccine to other countries on a business-to-business basis.
The company would also sell the vaccine in the domestic market after it had passed through a process at the Drug and Food Control Board (BPOM), she said.
"This vaccine will support Indonesia`s immunization program not only because it is complete but also more effective," she said.
She said an estimated 4.8 million infants in Indonesia would receive this vaccine.
Bio Farma, which is the only vaccine producer in Indonesia has set the sale target for 2012 at Rp1.4 trillion, an increase of 10-15 percent compared to last year.
Last year, the company booked a net profit of Rp303 billion and the figure is expected to increase to Rp408 billion this year.
(SYS/KR-BSR/S012)
Editor: Suryanto
Copyright © ANTARA 2012
